BackNuvalent Overview
Nuvalent Inc - Ordinary Shares - Class A

Nuvalent Target Price

Where could NUVL trade next? Consensus target price: $120.

Get informed when a big investor buys or sells

+ Follow

Share Price

$123.96

Average Target Price

$123.900.1% downside

11 analysts in the last 4 months

High: $124 | Low: $122.85

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-06-24Bernstein$1240% upsideOpen
2026-06-10GuggenheimBrad Canino$1240% upsideOpen
2026-06-10UBSDavid Dai$1240% upsideOpen
2026-06-09Wells FargoEva Fortea Verdejo$1240% upsideOpen
2026-06-09Truist Financial$1240% upsideOpen
2026-06-09Barclays$1240% upsideOpen
2026-06-09Robert W. Baird$122.850.9% downsideOpen
2026-06-09Stifel Nicolaus$1240% upsideOpen
2026-06-09Piper Sandler$1240% upsideOpen
2026-06-09Wedbush$1240% upsideOpen
2026-06-09H.C. Wainwright$1240% upsideOpen
2026-06-03Leerink PartnersAndrew Berens$16533.1% upsideOpen
2026-05-21Bernstein$18952.5% upsideOpen
2025-11-24Truist Financial$14012.9% upsideOpen
2025-11-17H.C. Wainwright$15525% upsideOpen
2025-11-17BarclaysEtzer Darout$15222.6% upsideOpen
2025-11-17Leerink Partners$14920.2% upsideOpen
2025-11-12Canaccord Genuity$1261.6% upsideOpen
2025-10-31Goldman Sachs$1203.2% downsideOpen
2025-10-31UBSDavid Dai$1326.5% upsideOpen
2025-10-27Piper SandlerKelsey Goodwin$1283.3% upsideOpen
2025-10-15Cantor FitzgeraldJosh Schimmer$1358.9% upsideOpen
2025-09-03Guggenheim$1221.6% downsideOpen
2025-09-02Raymond James$10515.3% downsideOpen
2025-06-24H.C. WainwrightSwayampakula Ramakanth$1304.9% upsideOpen
2024-11-13BMO CapitalEtzer Darout$1348.1% upsideOpen
2024-10-24UBSDavid Dai$10019.3% downsideOpen
2024-09-16GuggenheimKelsey Goodwin$10515.3% downsideOpen
2024-09-16Stifel NicolausBradley Canino$1358.9% upsideOpen
2024-09-16Raymond JamesChristopher Raymond$10019.3% downsideOpen
2024-07-10Stifel NicolausBradley Canino$1157.2% downsideOpen
2024-04-17JefferiesRoger Song$9721.7% downsideOpen
2024-04-01Leerink PartnersChristopher Liu$11011.3% downsideOpen

Nuvalent (NUVL) FAQ

Nuvalent's target price stands at $120. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $120 for NUVL implies 0.1% downside versus today's price ($123.96). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Nuvalent's target price evolved across reporting periods, while the comparison chart places NUVL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Nuvalent's reading of $120 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.